| ［1］ |
Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180⁃NC16a enzyme⁃linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients［J］. Arch Dermatol, 2011,147（3）: 286⁃291. DOI: 10.1001/archdermatol.2011.23.
|
| ［2］ |
Feng S, Wu Q, Jin P, et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid［J］. Int J Dermatol, 2008, 47（3）: 225⁃228. DOI: 10.1111/j.1365⁃4632.2008.03473.x.
|
| ［3］ |
Pfutze M, Niedermeier A, Hertl M, et al. Introducing a novel autoimmune bullous skin disorder intensity score （ABSIS） in pemphigus［J］. Eur J Dermatol, 2007,17（1）: 4⁃11. DOI: 10.1684/ejd.2007.0090.
|
| ［4］ |
Daniel BS, Hertl M, Werth VP, et al. Severity score indexes for blistering diseases［J］. Clin Dermatol, 2012, 30（1）: 108⁃113. DOI:10.1016/j.clindermatol.2011.03.017.
|
| ［5］ |
Rahbar Z, Daneshpazhooh M, Mirshams⁃Shahshahani M, et al. Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score［J］. JAMA Dermatol, 2014, 150（3）: 266⁃272. DOI: 10.1001/jamadermatol.2013.8175.
|
| ［6］ |
张洁尘, 冯素英, 王宝玺. 天疱疮疗效评估的研究进展［J］. 中华皮肤科杂志, 2012, 45（1）: 60⁃62. DOI: 10.3760/cma.j.issn.0412⁃4030.2012.01.028.
|
|
Zhang JC, Feng SY, Wang BX. Clinical outcome measures for pemphigus: an update［J］. Chin J Dermatol, 2012, 45（1）: 60⁃62. DOI: 10.3760/cma.j.issn.0412⁃4030.2012.01.028.
|
| ［7］ |
Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts［J］. J Am Acad Dermatol, 2012, 66（3）: 479⁃485. DOI: 10.1016/j.jaad.2011.06.032.
|
| ［8］ |
Patsatsi A, Kyriakou A, Pavlitou⁃Tsiontsi A, et al. Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid［J］. Clin Dev Immunol, 2012, 2012: 854795. DOI: 10.1155/2012/854795.
|
| ［9］ |
Zhao CY, Murrell DF. Outcome measures for autoimmune blistering diseases［J］. J Dermatol, 2015, 42（1）: 31⁃36. DOI: 10.1111/1346⁃8138.12711.
|
| ［10］ |
Lévy⁃Sitbon C, Barbe C, Plee J, et al. Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients［J］. Dermatology, 2014, 229（2）: 116⁃122. DOI: 10.1159/000362717.
|
| ［11］ |
Lee EH, Kim YH, Kim S, et al. Usefulness of enzyme⁃linked immunosorbent assay using recombinant BP180 and BP230 for serodiagnosis and monitoring disease activity of bullous pemphigoid［J］. Ann Dermatol, 2012, 24（1）: 45⁃55. DOI: 10.5021/ad.2012.24.1.45.
|
| ［12］ |
Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris［J］. J Am Acad Dermatol, 2000, 42（3）: 422⁃427.
|
| ［13］ |
赵邑, 刘晶, 姜薇, 等. 大疱性类天疱疮患者血清鳞状细胞癌抗原的检测［J］. 中国皮肤性病学杂志, 2010, 24（8）: 715⁃717.
|
|
Zhao Y, Liu J, Jiang W, et al. Serum squamous cell carcinoma antigen in bullous pemphigoid patients［J］. Chin J DermVenereol, 2010, 24（8）: 715⁃717.
|
| ［14］ |
Tsuji⁃Abe Y, Akiyama M, Yamanaka Y, et al. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid［J］. J Dermatol Sci, 2005, 37（3）: 145⁃149. DOI: 10.1016/j.jdermsci.2004.10.007.
|
| ［15］ |
金岩, 付海军, 翁孟武. HLA⁃Ⅱ类基因与大疱性类天疱疮的相关性研究［J］. 中华皮肤科杂志, 2003, 36（7）: 368⁃371. DOI:10.3760/j.issn:0412⁃4030.2003.07.002.
|
|
Jin Y, Fu HJ, Weng MW. Association of HLA⁃DRB1, DQA1, DQB1 in patients with bullous pemphigoid［J］. Chin J Dermatol, 2003, 36（7）: 368⁃371. DOI: 10.3760/j.issn:0412⁃4030.2003.07.002.
|
| ［16］ |
Schmidt E, Obe K, Brocker EB, et al. Serum levels of auto⁃antibodies to BP180 correlate with disease activity in patients with bullous pemphigoid［J］. Arch Dermatol, 2000, 136（2）: 174⁃178. DOI: 10.1001/archderm.136.2.174.
|
